Fig. 7: Shh inhibitor or Bcl2 inhibitor can be used as adjuvants to overcome Imatinib resistance imparted by CML patient’s BM-derived exovesicles. | Cell Death & Disease

Fig. 7: Shh inhibitor or Bcl2 inhibitor can be used as adjuvants to overcome Imatinib resistance imparted by CML patient’s BM-derived exovesicles.

From: Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes

Fig. 7

A Viability of K562 cell line treated with Exo or free-fractions derived from CML-CP patients (CML-1 or CML-8) or V-CML (CML-4 or CML-9) for 12 h, followed by treatment with 0.5 µM Imatinib (i), 25 nM Cyclopamine (iii), 50 nM Bcl2 inhibitor (v), or combined treatment (0.5 µM Imatinib + 25 nM Cyclopamine (ii) or 0.5 µM Imatinib + 50 nM Bcl2 inhibitor (iv)) for 72 h. Data represent mean ± SD from two different CML patient-derived fractions. P values, *<0.05 and **<0.01. Statistical analysis done using t-test. B Cartoon representing mechanism of secretion of different extracellular forms of Shh and Shh-mediated Imatinib resistance in leukemic cells. Available FDA-approved drugs indicated in red text, which can be used to overcome Shh-mediated therapy resistance.

Back to article page